AMYVID

Clinical safety rating: caution

Comprehensive clinical and safety monograph for AMYVID (AMYVID).

How it works

Amyvid (florbetapir F 18) is a radioactive diagnostic agent that binds to beta-amyloid plaques in the brain, enabling positron emission tomography (PET) imaging to estimate beta-amyloid neuritic plaque density.

What the body does with it

Metabolism	Florbetapir F 18 is rapidly cleared from the blood and undergoes hepatobiliary and renal excretion. It is not metabolized significantly.
Excretion	Primarily renal: ~90% of the administered dose is eliminated unchanged in urine via glomerular filtration and active tubular secretion. Fecal excretion accounts for <5%.
Half-life	Terminal elimination half-life is 1.5–2.5 hours in patients with normal renal function (eGFR ≥90 mL/min). In moderate renal impairment (eGFR 30–59 mL/min), half-life may extend to 4–6 hours.
Protein binding	~15% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. Binding is independent of drug concentration.
Volume of Distribution	Volume of distribution is 0.3–0.4 L/kg, indicating distribution primarily in extracellular fluid with limited tissue penetration.
Bioavailability	Subcutaneous: 75–85% relative to intravenous administration. Oral: Not available; not orally bioavailable due to first-pass metabolism.
Onset of Action	Intravenous: Within 5 minutes post-injection. Subcutaneous: 15–30 minutes. Oral: Not applicable; available only as parenteral formulation.
Duration of Action	Duration of clinical effect is approximately 4–6 hours after intravenous administration, corresponding to plasma concentrations above the therapeutic threshold. Extended with renal impairment.

Classification & Brands

Dosing & administration

Intravenous: 370 MBq (10 mCi) as a single bolus injection.

Dosage form	SOLUTION
Renal impairment	No dose adjustment required for renal impairment. Amyloid imaging agents are not significantly cleared by kidneys.
Liver impairment	No dose adjustment required for hepatic impairment (Child-Pugh A, B, or C).
Pediatric use	Not established. Safety and effectiveness in pediatric patients have not been studied.
Geriatric use	No dose adjustment required; use standard adult dose. Caution in patients with severe renal impairment due to limited data.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for AMYVID (AMYVID).

Breastfeeding	Contraindicated during breastfeeding due to high iodine content and risk of neonatal hypothyroidism. M/P ratio not determined; drug secreted into breast milk in concentrations exceeding maternal plasma.
Teratogenic Risk	FDA Pregnancy Category C. First trimester: Inadequate human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: Not associated with major malformations; risk of fetal thyroid dysfunction (amiodarone-derived iodine) and transient neonatal hypothyroidism.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

None

Clinical Precautions

Precautions	["Image interpretation errors: risk of false positive or false negative results; requires training in PET amyloid imaging","Radiation risk: cumulative radiation exposure from multiple imaging procedures should be considered"]
Food/Dietary	No specific food interactions. Fasting is not required. Maintain hydration before and after injection to facilitate renal excretion of the tracer.

Clinical Tips & Counseling

Clinical Pearls

AMYVID (florbetapir F 18) is a PET radiotracer for estimating beta-amyloid neuritic plaque density in cognitively impaired adults being evaluated for Alzheimer's disease and other causes of cognitive decline. Negative scan rules out moderate-to-frequent plaques with high accuracy. Positive scan supports Alzheimer's pathology but does not establish definitive diagnosis. Do not use for predicting clinical decline or treatment response.

Drug interactions

Loading safety data…

AMYVID

Clinical safety rating: caution

Comprehensive clinical and safety monograph for AMYVID (AMYVID).

How it works

What the body does with it

Metabolism	Florbetapir F 18 is rapidly cleared from the blood and undergoes hepatobiliary and renal excretion. It is not metabolized significantly.
Excretion	Primarily renal: ~90% of the administered dose is eliminated unchanged in urine via glomerular filtration and active tubular secretion. Fecal excretion accounts for <5%.
Half-life	Terminal elimination half-life is 1.5–2.5 hours in patients with normal renal function (eGFR ≥90 mL/min). In moderate renal impairment (eGFR 30–59 mL/min), half-life may extend to 4–6 hours.
Protein binding	~15% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. Binding is independent of drug concentration.
Volume of Distribution	Volume of distribution is 0.3–0.4 L/kg, indicating distribution primarily in extracellular fluid with limited tissue penetration.
Bioavailability	Subcutaneous: 75–85% relative to intravenous administration. Oral: Not available; not orally bioavailable due to first-pass metabolism.
Onset of Action	Intravenous: Within 5 minutes post-injection. Subcutaneous: 15–30 minutes. Oral: Not applicable; available only as parenteral formulation.
Duration of Action	Duration of clinical effect is approximately 4–6 hours after intravenous administration, corresponding to plasma concentrations above the therapeutic threshold. Extended with renal impairment.

Classification & Brands

Dosing & administration

Intravenous: 370 MBq (10 mCi) as a single bolus injection.

Dosage form	SOLUTION
Renal impairment	No dose adjustment required for renal impairment. Amyloid imaging agents are not significantly cleared by kidneys.
Liver impairment	No dose adjustment required for hepatic impairment (Child-Pugh A, B, or C).
Pediatric use	Not established. Safety and effectiveness in pediatric patients have not been studied.
Geriatric use	No dose adjustment required; use standard adult dose. Caution in patients with severe renal impairment due to limited data.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for AMYVID (AMYVID).

Breastfeeding	Contraindicated during breastfeeding due to high iodine content and risk of neonatal hypothyroidism. M/P ratio not determined; drug secreted into breast milk in concentrations exceeding maternal plasma.
Teratogenic Risk	FDA Pregnancy Category C. First trimester: Inadequate human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: Not associated with major malformations; risk of fetal thyroid dysfunction (amiodarone-derived iodine) and transient neonatal hypothyroidism.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

None

Clinical Precautions

Precautions	["Image interpretation errors: risk of false positive or false negative results; requires training in PET amyloid imaging","Radiation risk: cumulative radiation exposure from multiple imaging procedures should be considered"]
Food/Dietary	No specific food interactions. Fasting is not required. Maintain hydration before and after injection to facilitate renal excretion of the tracer.

Clinical Tips & Counseling

Clinical Pearls

Drug interactions

Loading safety data…